Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | IL6ST | P40189 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940114 | 1.00 | NAAA (0.45) | NAAAFAAHIDH1PPARAPPARG | |
| SCHEMBL2883438 | 0.87 | NAAA (0.42) | NAAAFAAHIDH1PPARAPPARG | |
| SCHEMBL8274823 | 0.85 | NAAA (0.47) | NAAAFAAHIDH1PPARAPPARG | |
| SCHEMBL17222076 | 0.85 | NAAA (0.47) | NAAAFAAHIDH1PPARAPPARG | |
| SCHEMBL13316598 | 0.85 | NAAA (0.47) | NAAAFAAHIDH1PPARAPPARG | |
| SCHEMBL2501454 | 0.85 | NAAA (0.48) | NAAAFAAHIDH1PPARAIL6ST | |
| SCHEMBL2501460 | 0.85 | NAAA (0.48) | NAAAFAAHIDH1PPARAIL6ST | |
| SCHEMBL46356 | 0.85 | NAAA (0.48) | NAAAFAAHIDH1PPARAIL6ST | |
| SCHEMBL7306476 | 0.84 | NAAA (0.47) | NAAAFAAHIDH1PPARAIL6ST | |
| SCHEMBL4238770 | 0.84 | NAAA (0.40) | NAAAFAAHIDH1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8933109-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8552202-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8389737-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| EP-2283022-A1 | FURO Ý3, 2-B¨PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | Amura Therapeutics Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | NAAA 1685/4885FAAH 228/4885IDH1 4866/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | NAAA 1329/4885FAAH 137/4885IDH1 4869/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | NAAA 1685/4885FAAH 228/4885IDH1 4866/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | NAAA 1685/4885FAAH 228/4885IDH1 4866/4885 |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | NAAA 1685/4885FAAH 228/4885IDH1 4866/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | NAAA 1329/4885FAAH 137/4885IDH1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.